Related Experiment Video
Updated: Mar 22, 2026
06:20
Murine Bilateral Renal Lymphadenectomy
Published on: December 30, 2025
132
New therapeutic avenues in SLE
Jyoti Bakshi1, Mediola Ismajli1, Anisur Rahman1
1University College London, London, UK.
Best Practice & Research. Clinical Rheumatology
|April 25, 2016
Summary
New biologic therapies targeting B cells show promise for improving systemic lupus erythematosus (SLE) outcomes. While anti-T-cell and anti-cytokine treatments are less advanced, future decades may bring further therapeutic breakthroughs.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) management has improved with corticosteroids and immunosuppressants, but new therapies are needed.
- SLE pathogenesis involves complex immune system components, including B cells, T cells, cytokines, and innate immunity, offering multiple targets for novel treatments.
Purpose of the Study:
- To review the rationale for developing new biologic therapies for SLE.
- To describe the progress made in various therapeutic directions for SLE treatment.
Main Methods:
- Review of existing literature on SLE pathogenesis and therapeutic targets.
- Analysis of clinical trial data for emerging biologic agents in SLE.
Main Results:
- Significant progress observed in B-cell-targeted therapies, with rituximab and belimumab showing efficacy.
- Belimumab has demonstrated success in two randomized clinical trials (RCTs) for SLE.
- Anti-T-cell and anti-cytokine therapies are in earlier stages of development but show future potential.
Conclusions:
- B-cell-targeted biologics represent a promising advancement in SLE treatment.
- Further research and development in anti-T-cell and anti-cytokine therapies are anticipated to yield new treatment options for SLE in the coming decade.
Related Concept Videos
01:29Autoimmune Disorders
2.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.1K
01:26Nephrotic Syndrome II : Assessment and Medical Management
306
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
306
01:29Inflammatory Bowel Disease IV: Pharmacological Management
910
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
910
01:24Nephrotic Syndrome III : Nursing Management
428
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
428
01:20The JAK-STAT Signaling Pathway
13.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.7K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K